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The aim of this multi-centre UK study is to examine the attributes of a cohort offered predictive genetic testing for breast/
ovarian cancer predisposition. Participants are adults unaffected with cancer from families with a known BRCA1/2 mutation.
This is the ﬁrst large multi-centre study of this population in the UK. The study evaluates mental health, perceived risk of
developing cancer, preferred risk management options, and motivation for genetic testing. Participants were assessed when
coming forward for genetic counselling prior to proceeding to genetic testing. Three hundred and twelve individuals, 76% of
whom are female, from nine UK centres participated in the study. There are no gender differences in rates of psychiatric
morbidity. Younger women (550 years) are more worried about developing cancer than older women. Few women provide
accurate ﬁgures for the population risk of breast (37%) or ovarian (6%) cancer but most think that they are at higher risk of
developing breast (88%) and ovarian (69%) cancer than the average woman. Cancer related worry is not associated with
perceived risk or uptake of risk management options except breast self-examination. The ﬁndings indicate that younger
women may be particularly vulnerable at the time of the offer of a predictive genetic test.
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Predictive genetic testing is available to some individuals unaffected
with cancer where a BRCA1/2 mutation has been identiﬁed in the
family (Miki et al, 1994; Wooster et al, 1995). Female gene muta-
tion carriers not already affected by cancer have up to 85% and
27–60% chance of developing breast and ovarian cancer respec-
tively in their lifetime (Ford et al, 1998). They are at higher risk
of early onset (often pre-menopausal) and bilateral breast cancer
compared to women at population risk (Ford et al, 1998). Male
carriers have a slight increased risk of prostate and bowel cancer
(Ford et al, 1994) and male BRCA2 carriers have an estimated
6% risk of developing breast cancer by the age of 70 years (Easton
et al, 1997). The medical and psychological management of indivi-
duals eligible for predictive genetic testing must ensure that
individuals are well prepared to enable them to make informed risk
management decisions and minimise psychological distress experi-
enced during the pre-test period.
Data from studies investigating predictive genetic testing for
BRCA1/2 are relatively few at present. Most suggest that individuals
taking up the offer of a predictive genetic test for BRCA1/2 are female
(around 80%) and in their early to mid 40s (Lerman et al, 1997;
Reichelt et al, 1999). Much of the literature focuses on highly
researched individuals who participated in linkage studies (Croyle
et al, 1997; Lerman et al, 1997). It is likely that important differences
exist between individuals from ‘research’ families, where relatives are
likely to be better informed and prepared for genetic testing,
compared with those currently involved in testing. Adverse psycholo-
gical effects of genetic testing may be more likely among individuals
with less knowledge and risk awareness (Croyle et al, 1997). Levels of
psychological morbidity and cancer speciﬁc worry in those presenting
for genetic testing must be clariﬁed to ensure they are well prepared,
supported and able to cope with genetic test results.
Men and hereditary breast and ovarian cancer
Men in families with hereditary breast/ovarian cancer (HBOC) can
inherit a BRCA1/2 mutation and pass it on to their daughters and
sons. DuDok de Wit et al (1996) described the psychological
impact of HBOC on men in a small study of one family involved
in linkage research. They suggest men may not come forward for
genetic testing due to their low risk of developing cancer. In addi-
tion, minimisation and denial of the threat may lead men to avoid
testing or fail to ask for support. Few studies have documented the
attributes of men opting for genetic counselling and testing there-
fore a study including a substantial male cohort is needed.
Mental health and cancer related worry
Women at high risk of HBOC may bear a heavy emotional burden
due to their familial experiences of cancer, high bereavement rates
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www.bjcancer.comand their own fears of developing the disease. Some women at
increased risk of HBOC who have not yet been offered a genetic
test experience high levels of distress (Lerman et al, 1993; Lloyd
et al, 1996). Those proceeding with predictive genetic testing do
not report higher levels of general distress (depression or anxiety)
than women with one affected ﬁrst-degree relative (Lerman et al,
1997) or population norms (Croyle et al, 1997). However, women
have reported high levels of cancer speciﬁc distress prior to receiv-
ing a test result. Those most likely to report such distress at this
time are young, more likely to anticipate problems if identiﬁed
as a gene carrier, more likely to consider prophylactic mastectomy
and more aware of the serious consequences of HBOC (Lodder et
al, 1999). Cancer-related worry has been associated with increased
interest in testing (Lerman et al, 1997).
Risk perception
Women with HBOC tend to overestimate their risk of developing
cancer despite genetic counselling (Evans et al, 1993; Watson et al,
1999). Cancer related distress (Lerman et al, 1995) and individual
characteristics may interfere with comprehension of individualised
genetic risk information. Research focusing on minority women
from low-income households suggests that they are less likely to
recognise breast cancer risk factors (Royak-Schaler et al, 1995). If
genetic testing is to provide beneﬁts it is important to ensure that
those offered testing understand risk information and the advice
given so that informed choices can be made in relation to risk
management.
Risk management
An important goal of predictive genetic testing is to help reduce
mortality through early detection. There is limited evidence for the
efﬁcacy of mammography for pre-menopausal women. Recent
evidence shows a beneﬁt in women over 40 years (Duffy et al,
1996). Magnetic resonance imaging screening may be more sensitive
in pre-menopausal women than mammography (Stoutjesdijk et al,
2001). Demographic variables such as age, education and ethnicity
have been associated with differing levels of screening uptake
(MacLean et al, 1984; Owens et al, 1987). Some women may opt
for primary prevention strategies such as prophylactic surgery. The
effectiveness of chemoprevention (e.g. tamoxifen) for female carriers
of BRCA1/2 mutations is not yet known (Eeles and Powles, 2000).
The role of anxiety and risk perception in risk management
Anxiety and misunderstanding of risk information may inﬂuence
how individuals make use of risk management advice. Cancer
related worry among relatives of breast cancer patients can interfere
with adherence to breast screening recommendations (Alagna et al,
1987; Kash et al, 1992). However, the nature of the relationship
between cancer worry and uptake of risk management options is
unclear. Alagna et al (1987) report a curvilinear relationship
between cancer worry and uptake of mammography where women
with moderate levels of distress were more likely to engage in
mammography than those with low or high levels.
Overestimation of risk is a potential barrier to screening. Kash et
al (1995) found a negative correlation between perceived suscept-
ibility and rate of breast self examination (BrSE), mammography
and clinical breast examination (CBE: examination of breasts by
a doctor) among women from families with HBOC. Different
forms of risk management behaviour may be affected in different
ways by cancer-related concerns and perceived risk.
Reasons for predictive genetic testing
Reasons given by women undergoing BRCA1/2 testing include:
obtaining certainty about carrier status; increasing the level of
screening or to have prophylactic surgery; and learning about their
children’s risk (Lodder et al, 1999). An exploration of reasons for
proceeding with genetic testing is needed within a cohort that is
potentially less well informed than well-researched individuals
and one that includes men.
The present study includes men and women from nine hospitals
in England, Scotland and Northern Ireland that currently under-
take the majority of BRCA1/2 testing in the UK. This cohort is
representative of current clinical practice as few participants come
from well-researched families. This is in contrast to much of the
literature, which largely focuses on well-researched women. The
study aim is to document mental health problems, clarify levels
of cancer related distress, ascertain risk perceptions and examine
ongoing and anticipated risk management behaviour in those
offered genetic testing. Four key questions are addressed: (1) What
are the levels of mental health problems and cancer related worry
in a clinical cohort offered BRCA1/2 testing?; (2) Do women accu-
rately estimate their risks of developing breast/ovarian cancer and
are these related to cancer speciﬁc worry?; (3) What risk manage-
ment behaviours do women engage in (or anticipate) and is this
related to cancer worry and risk perception?; and (4) What is
the motivation for predictive genetic testing and does this differ
for men and women?
METHODS
Participants
Participants included 315 adults from nine UK clinical genetic
centres. Those eligible were 518 years, from families in which a
BRCA1/2 mutation had been identiﬁed, had no previous diagnosis
of cancer, and no current mental illness likely to be exacerbated by
study participation.
Procedure
This study was conducted as part of the baseline component of a
large, prospective evaluation of BRCA1/2 testing in the UK. Eligible
participants have a 50% (lower if an intervening relative has died)
risk of inheriting a BRCA1/2 mutation. They are usually referred by
their GP after learning of the mutation in the family. Some at risk
individuals were directly informed of the availability of testing if
they were already under the genetics service. They were recruited
to the present study by their clinical geneticist or genetic associ-
ate/nurse between 1996 and 2000 during their clinic consultation
(prior to the consultation at which blood was drawn for genetic
analysis). Written informed consent was obtained. Participants
were given a questionnaire to complete and return directly to the
data management centre at the Institute of Cancer Research/Royal
Marsden NHS Trust. The multi-centre research ethics committee
(98Jan003) and all local research ethics committees approved the
study.
Measures
Measures were selected for validity, reliability and prior application
to the study population along with a number of study-speciﬁc
questions. The following pre-validated measures were included:
General Health Questionnaire (GHQ28: Goldberg and Hillier
1979): a brief 28-item instrument designed to assess psychiatric
disorder (cases) in non-psychiatric populations previously used
with medical patients. The GHQ28 includes four sub-scales:
somatic symptoms, anxiety and insomnia, social dysfunction, and
severe depression. A total score on the GHQ28 (binary scoring)
ranges from 0–28. A cut-off score of 55 is recommended by
the test authors i.e. a score 55 indicates psychiatric disorder.
However, Hopwood et al (1998) recommend a threshold of 510
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tion of cases. We report the 10-point cut-off.
Cancer Worry Scale (CWS: Lerman and Schwartz, 1993): this
four-item scale assesses degree of worry about developing cancer
(women only) using a 4-point Likert rating from ‘Not at all or
rarely’ to ‘Almost all the time’. Two further items previously used
elsewhere were included to ask about frequency of worry from ‘Not
at all or rarely’ to ‘Constantly’ and how much of a problem this
worry is from ‘Not at all’ to ‘Severe problem’ (Watson et al,
1999). This Revised 6-item Cancer Worry Scale (CWS-R) yields
an internal reliability alpha coefﬁcient of 0.87 (n=226 women).
Maximum likelihood factor analysis explains 61% of the variance
and a signiﬁcant goodness of ﬁt test w
2 (df=9)=25.75, P=0.003. A
total score on the CWS-R ranges from 6–24. A high score indi-
cates greater worry. No clinical cut-offs are currently available.
Impact of Event Scale (IES: Horowitz et al, 1979): this scale
determines levels of distress in response to a speciﬁc traumatic
event. A modiﬁed 15-item version has previously been used to
gather information on cancer-speciﬁc distress in high-risk and
general population women (Kash et al, 1992; Watson et al,
1999). The IES was included to assess psychological response, with
speciﬁc reference to thoughts about risk of cancer (women only)
over the last 7 days. Total scores on the Intrusion and Avoidance
scales range from 0–35 and 0–40 respectively. A high score indi-
cates frequent intrusive/avoidant thoughts about risk of cancer.
Risk perception Perceived risk of developing breast/ovarian cancer
(women only) was assessed in terms of the likelihood of developing
breast/ovarian cancer (3-point scale: ‘Not very likely’ to ‘Very likely’
or as a percentage or odds ratio) and relative risk compared to the
average woman (5-point scale: ‘Very much lower’ to ‘Very much
higher’). Knowledge of general population risk of breast/ovarian
cancer was assessed by the question ‘Do you know what the average
woman’s risk is of breast/ovarian cancer throughout her lifetime?’
with response options ‘No’, ‘Yes – please specify’.
Risk management Women were asked to indicate their current
risk management practices and options they might consider should
they be gene carriers. These included: mammography, chemo-
prevention (participating in tamoxifen trial), prophylactic surgery,
ultrasound, CBE, BrSE or any other screening for cancer. For BrSE
women were asked about frequency. Barriers to screening were
assessed using a 5-point scale from ‘Not difﬁcult’ to ‘Very difﬁcult’
including: physical discomfort, fear of examination, transport to
screening clinic, distress caused by screening, and taking time from
work/family/social obligations to attend (Kash et al, 1992).
Other measures Study speciﬁc questions asked about reasons for
wanting a genetic test (multiple choice) and whether participants
considered themselves to be at increased risk of other cancers.
Expectations about gene carrier status were assessed (‘certain I will
not have the gene’, ‘uncertain’ and ‘certain I will have the gene’)
and means of referral to the genetics clinic.
Statistical methods
The association between categorical variables was examined by
means of Fisher’s exact test or the chi-squared test (w
2) with Yates
correction. For ordered categorical variables the Mann–Whitney
(MW) test for trend was used. Age was analysed as a continuous
variable and, in addition, subjects were divided into three age
groups (535, 35–49, 550 years). These three groups were chosen
as risk management options vary for women in each group.
Women under 35 years are unlikely to receive a mammogram
and women over 50 years of age receive regular mammograms as
part of the UK National Screening Programme.
Scores from the GHQ28, CWS-R and IES were treated as
continuous variables. Normality was tested using the Kolmogor-
ov-Smirnov statistic and parametric or non-parametric statistics
were used as appropriate. Scores were summarised using mean
(m) and standard deviation (s.d.) or median and range (in tables
mean values have been quoted because of the relative invariance
of the median). Groups were compared using analysis of variance
or the Kruskal-Wallis (KW) test. Associations between psychologi-
cal scores were summarised by the Pearson or Spearman
correlation coefﬁcients. The inﬂuence of a number of factors in
predicting whether women practised BrSE was investigated in a
multivariate logistic regression analysis. Subjects with missing data
were omitted from the respective analyses.
RESULTS
Three hundred and ﬁfteen participants met study entry criteria;
three declined (response rate 99%). Six participants were retrospec-
tively identiﬁed as decliners of genetic testing (i.e. following their
genetic counselling session) and therefore did not receive a ques-
tionnaire. Nine individuals did not return their questionnaire
leaving a total of 298 (97%) completed questionnaires received
(227 females; 71 males).
Characteristics of the cohort
Participants at each centre were compared on demographic vari-
ables. Three centres (Manchester, London/Sutton and
Southampton) accounted for 81% of the participants. Two of the
smaller centres (Cambridge and Birmingham) only recruited
women. There are no differences between the three larger centres
(Manchester, London/Sutton and Southampton) except for
London/Sutton patient’s having a higher level of educational
achievement than those from Southampton (P=0.02; MW) i.e.
more of the London/Sutton participants attended college or univer-
sity than the Southampton participants. Participants from the six
smaller centres (n=57) are younger (P=0.001; MW) and have
younger daughters (P=0.03; MW) than those from the three larger
centres.
Seventy-six per cent of the cohort are women. Eighty-two per
cent of participants are married or living with a partner. Over
one third have a college or university education. Most men
(75%) and women (66%) are currently employed. The median
age for women is 41 (21–72 years), and 48 (22–86 years) for
men. In the three age groups: 53 women and 14 men are 535
years; 120 women and 24 men 35–49 years; 54 women and 33
men 550 years. Most participants have children (87%). The
median age of offspring is 19 (range 0–50 years). Eighty-ﬁve per
cent of participants described themselves as white.
Type of referral
Participants were asked whose idea it was to attend the genetics
clinic: 184 (63%) reported self-referral, 42 (14%) their family’s
idea, 12 (4%) GP recommendation and 31 (11%) referrals came
from a genetics clinic. There were no signiﬁcant gender differences
in referral. Type of referral was not associated with general mental
health (P=0.7; KW), cancer worry (P=0.9; KW), avoidant (P=0.7;
KW) or intrusive (P=0.2; KW) thoughts, age (P=0.8; KW) or
number of children (P=0.3; KW).
General mental health and cancer related worry
The GHQ28, CWS-R and IES (Table 1) assessed general mental
health and cancer related concerns. Using a cut-off of 510
(Hopwood et al, 1998) on the GHQ28, 22 (10%) females and ﬁve
(7%) males met criteria for psychiatric disorder. Using the 5-point
cut-off , 49 (22%) women and 10 (14%) men met the criteria for
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of psychiatric morbidity.
Younger women expressed higher levels of cancer worry (550,
median 12) than older women (550, median 10) (P50.001;
MW). There was no difference between the two younger groups
(535 median 12; 35–49 median 11; P=0.9; MW). Forty-eight
(21%) women stated that they worried about developing cancer
‘frequently’ or ‘constantly’ and 38 (17%) felt that their cancer-
related worry was a ‘deﬁnite’ or ‘severe’ problem. Compared with
older women, younger women worried more often (550 years,
26% 550 years, 7%; P=0.04 w
2) and found it more of a problem
(550 years, 21%; 550 years, 4%; P=0.006 w
2). CWS-R and
GHQ28 scores were positively correlated (0.4, P=0.01).
There were positive correlations (Pearson) between IES scales
and GHQ28 (avoidance 0.4, P50.01; intrusion 0.4, P50.01) and
CWS-R (avoidance 0.7, P50.01; intrusion 0.5, P50.01) scores.
There was no effect of age on intrusion (P=0.5; KW) or avoidance
(P=0.6; KW) scores. Fifty women (24% of the 205 women with an
intrusion score) reported a total absence of intrusive thoughts
(intrusion score=0). Thirty-six women (17% of the 207 with an
avoidance score) recorded an avoidance score of 0.
Risk perception
Own risk Compared with the average woman, 197 (88%) and
153 (69%) thought they were at higher/much higher risk of devel-
oping breast and ovarian cancer respectively. Thirty (14%) and 70
(32%) women considered it not very likely that they would develop
breast and ovarian cancer respectively. There was no relationship
between perceived risk and GHQ28, CWS-R or IES scores. Self
referred women (n=143) had higher perceived risk of breast cancer
(not ovarian) with 97% of women reporting higher than average
risk compared to 81% of the other referral groups (n=79;
P=0.03; MW). Younger women (550 years) have a higher
perceived risk of breast (P=0.0005; MW) and ovarian (P=0.05;
MW) cancer than older women.
Population risk Sixty and 26% of women were able to give a
ﬁgure for population risk of breast and ovarian cancer respectively.
Of these, only 38% gave a correct estimate for breast (deﬁned as
odds ratio of 1 in 11–15) and 8% for ovarian cancer (deﬁned as
odds ratio of 1 in 50–100). Eighteen per cent and 16% of women
overestimated the population risk of breast and ovarian cancer
respectively. Only 4% and 1% of women underestimated popula-
tion risk of breast and ovarian cancer respectively. Higher
educational status was associated with accurate ﬁgures for popula-
tion breast cancer risk. Forty-nine per cent of college/university
educated participants were correct compared to 33% of those
who were school educated (P=0.004; w
2). The corresponding
ﬁgures for ovarian cancer were 14% college/university and 7%
school educated (P=0.01). Age had no effect on accuracy of popu-
lation ovarian cancer risk ﬁgures but younger women were more
likely to give a correct ﬁgure for population breast cancer risk
(550 years, 43%; 550 years, 23%; P=0.001; w
2).
Risk of other cancers
Fifty-four (24%) women and 24 (34%) men felt that they were at
increased risk of developing other cancers. Bowel (24 women, 13
men), prostate (12), lung (11 women, one man) and other gynae-
cological cancers (four) were the most common cancers
mentioned.
Risk management behaviour
Table 2 illustrates the tests and procedures that women have ever
had according to their self-reports and those that they may consid-
er if they are found to be a gene carrier. This is shown according to
age group. Risk management strategies were considered in relation
to age and level of cancer-related worry.
Current risk management These women reported having had a
mammogram an average of 9 months previously (range 0 mn–10
years); a CBE an average of 7 months previously (range 0 mn–21
years). One woman reported having a bilateral mastectomy 2 years
before (the other two do not report a date); ovarian ultrasound an
average of 5 months previously (range 0 mn–7 years); and bilateral
oophorectomy an average of 3 years previously (range 7 mn–9
years). One hundred and ninety-eight (88%) women reported
performing BrSE; 22 (10%) more than once a week, 49 (22%)
more than once a month, 68 (30%) monthly, 51 (22%) less
frequently. Older women (550 years) examined their breasts less
frequently than the under 35 years (P=0.02) and the 35–49 groups
(P50.001; MWTrend). Two hundred and twenty-two (98%) women
reported having had a cervical smear. Older women (550 years)
were less likely to report having had a cervical smear than younger
women (P=0.001; w
2). Twenty-nine (13%) women reported other
tests for cancer including biopsy (n=1), breast ultrasound (n=3),
blood tests (n=2), CA125 (n=2), MRI (n=2), pelvic ultrasound
(n=2), colonoscopy (n=4), and ‘other’ (not speciﬁed, n=7). These
procedures were marginally more common in older women
(550 years; P=0.06; w
2).
Cancer-related worry was not associated with a higher level of
risk management activity (i.e. women that had already had a proce-
dure were not more worried than those who had not) other than
for women performing BrSE. Women practising BrSE had a higher
level of cancer related worry than those that did not (P=0.008;
MW). A logistic regression analysis (adjusted for level of cancer
worry) indicated that no other variables predicted BrSE where
age, educational status, marital status, number of children, percep-
C
l
i
n
i
c
a
l
Table 1 General mental health (GHQ28) and cancer speciﬁc worry (CWS-R and IES)
scores
Age group
535 years 35–49 years 550 years Signiﬁcance
a
GHQ Females Mean (s.d.) 2.6(3.6) 3.1(4.5) 2.2(4.0) P=0.2
GHQ Males Mean (s.d.) 0.3(0.6) 1.6(2.6) 2.4(4.2) P=0.3
GHQ case (510) n Female 3(6%) 13(11%) 6(12%) P=0.3
n Male 0 1(4%) 4(12%) P=0.1
CWS-R
b Mean (s.d.) 11.8(3.2) 12.1(3.5) 10.2(2.5) P=0.003
IES-Intrusion
b Mean (s.d.) 5.0(5.4) 4.9(4.7) 5.6(4.2) P=0.5
IES-Avoidance
b Mean (s.d.) 6.9(5.5) 6.1(5.3) 5.9(4.6) P=0.6
aSigniﬁcance is assessed by the KW.
bFemales only.
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and other risk management strategies were entered as variables.
Anticipated risk management If they were found to be a
BRCA1/2 carrier younger women (535 years) were more likely
to consider prophylactic mastectomy than older women (535
years; P=0.03; w
2). There was no relationship between cancer worry
and anticipated risk management behaviour following the test
result (MW). Comparing the number of women who had had
the procedure, mammography was less common in younger
women (535 years; P=0.004; w
2).
Barriers to screening
Women were asked to rate a number of factors that might make it
difﬁcult to attend for screening (Table 3). Taking time off work/
family/social obligations was recorded as the factor causing most
difﬁculty with 21% of women scoring 3–5. Older women were less
likely to report taking time off work as a barrier (550 years, 13%;
550 years, 40%; P=0.001; MWTrend). ‘Fear of the examination’ was
more of a barrier to screening in the younger age group (535
years, 25%; 535 years, 9%; P=0.002; MWTrend). There were no
other age differences.
Reasons for testing
Reasons for wanting a genetic test are presented in Table 4. Most
women (81%) and men (91%) with children reported ‘for the sake
of the children’. Mothers of daughters and older women were more
likely to endorse ‘for the sake of the children’ than mothers of sons
only (daughters 84%; sons 66%; P=0.02; Fisher) or younger
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Table 2 Tests and procedures women have ever had (self-report) and those they
would consider if found to be a BRCA1/2 mutation carrier
Age group Done/in Would consider
(years) n-replies progress (%) the procedure (%)
Mammography 535 49 29 59
35–49 112 46 50
550 54 61 39
CBE 535 48 35 60
35–49 112 48 57
550 51 48 43
Tamoxifen (trial) 535 48 0 29
35–49 103 2 27
550 40 10 20
Bilateral mastectomy 535 48 2 42
35–49 108 2 25
550 44 0 27
Ovarian ultrasound 535 48 8 77
35–49 103 32 49
550 38 26 66
Bilateral oophorectomy 535 48 2 40
35–49 106 10 41
550 44 30 32
Cervical smear 535 52 100 Not asked
35–49 118 100
550 54 93
Other screening 535 51 10 Not asked
35–49 118 11
550 54 20
BrSE 535 52 85 Not asked
35–49 117 91
550 54 83
Table 3 Barriers to screening (women)
Level of difﬁculty in attending for
screening
% scoring
1 not at all 2 3 4 5 very 3–5
Physical discomfort 180 17 15 3 3 10%
Fear of examination 189 17 7 3 1 5%
Transport problem 188 12 12 3 2 8%
Emotionally distressing 175 25 11 1 4 7%
Taking time off work 144 28 23 11 11 21%
Table 4 Reasons for wanting the test (men and women)
Female Male
n (227) % n (71) % Signﬁcance
a
Not sure want test 11 5 2 3 P=0.7
To stop disease 54 24 12 17 P=0.3
Prepare for the future 111 49 19 27 P=0.001
Relieve uncertainty 149 66 34 48 P=0.008
For the sake of the children
b 152 81 49 91 P=0.14
Decision about having children
c 11 6 6 16 P=0.09
Research 129 57 41 58 P=1.0
Other 13 6 3 4
aSigniﬁcance is assessed by Fisher’s exact test.
bFigures and % relate to subjects who
have children only (n female=187, male=54).
cFigures and % relate to subjects ages
550 years only (n female=171, male=38). Percentages have been rounded up to the
nearest whole number.
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P=0.005; MWTrend). In the two younger groups, women under
35 years were more likely to endorse ‘to make decisions about
having children’ (535 years, 14%; 35–49 years, 3%; P=0.01; Fish-
er). Older women were less likely to give ‘to prepare for the future’
(550 years, 31%; 550 years, 54%; P=0.005; Fisher). There were
no other age differences between women. Women were more likely
than men to want the test in order to prepare for the future
(women, 49%; men, 27%; P=0.001; Fisher) and to relieve uncer-
tainty (women, 66%; men, 48%; P=0.008; Fisher). Childless men
and women were more likely to give ‘decisions about having chil-
dren’ as a reason for wanting the test than those who were parents
(women 67% vs 9%; P=0.001: men 67% vs 4%; P=0.007; Fisher).
There was no relationship between psychiatric morbidity (GHQ)
and reasons for wanting the genetic test.
When asked how certain they are about having a BRCA1/2
mutation the majority (75%) were uncertain, 22% were certain,
and 3% certain that they did not. More women than men were
certain (women, 25%; men, 12%; P= 0.03; Fisher).
DISCUSSION
The aim of this multi-centre UK study is to examine the attributes
of those who present for genetic testing for BRCA1/2. The most
vulnerable group in this cohort is young women who report more
cancer worry than older women. Worry about cancer is not asso-
ciated with risk perception but it does impact on self-reported
BrSE. Women who are more worried about developing cancer
are most likely to perform BrSE.
Mental health and cancer related worry
In this cohort women are more likely to report cancer speciﬁc distress
than general psychological distress. This reﬂects ﬁndings from
previous research (Kash et al, 1992; Croyle et al, 1997; Lerman et
al, 1997). Younger women report more cancer speciﬁc worry than
older women which is consistent with the literature (Lerman et al,
1993; Lloyd et al, 1996). A signiﬁcant proportion of younger women
(550 years) worry more often about developing cancer and ﬁnd it
more of a problem than older women. In contrast, Lodder et al
(1999) found that age was not associated with cancer speciﬁc distress
although they did ﬁnd that younger women had higher levels of
general anxiety. In our cohort men and women do not report
unusually high levels of general distress although these ﬁgures may
be conservative given the raised GHQ28 threshold.
Most women in our study report some intrusive and avoidant
thoughts about developing cancer and the numbers of women
reporting no such thoughts are similar to Lodder et al (1999).
However, the women in this cohort do not score as highly as those
in Reichelt et al (1999) study although it is not clear from that
study what they were asking women to rate on the IES. In our
study women were asked to rate responses in relation to their risk
of developing cancer. During genetic counselling prior to predictive
genetic testing for BRCA1/2 it is important to ensure that decisions
to proceed with genetic testing are informed and not motivated
purely by cancer related worry. In this way impulsive decisions
about testing that may be poorly informed can be avoided. Breast
and ovarian cancer related concerns must be addressed prior to
genetic testing. This is not to say that worry can or should be
eliminated as concern about developing cancer given the family
history is not surprising. However, it is important to ensure that
appropriate services are in place to identify individuals most likely
to need extra psychological support.
Risk perception
To optimise health beneﬁts individuals should understand risk
information presented in genetic counselling so that informed deci-
sions can be made regarding risk management. A signiﬁcant
proportion of women overestimate the population risk of breast
and ovarian cancer. This is consistent with the literature (Evans
et al, 1993; Watson et al, 1999). Younger women are more likely
to provide an accurate ﬁgure for breast but not ovarian cancer risk.
Most women in our study think it likely they will develop breast/
ovarian cancer and that their risk is higher than the average
woman. Self-referred women are more likely to think of themselves
as at higher risk than those in the other referral groups. A higher
perception of risk is related to the expectation of being a gene
carrier. Lerman et al (1994) report that most women continue to
overestimate their risk following genetic counselling, particularly
those with high levels of concern about breast cancer. In this UK
cohort cancer related worry was not associated with risk percep-
tion. This may be because the women in this study are eligible
for predictive genetic testing and considering being tested and most
of them consider themselves to be at increased risk. As such, given
the low variation in risk perception scores it is difﬁcult to assess
the relationship between cancer worry and perception of risk at
baseline.
Risk management
In our study cancer related worry is positively associated with a
higher level of BrSE but not with any other risk management
option. In contrast to the literature (Alagna et al, 1987) we did
not ﬁnd a curvilinear relationship for mammography or other
health behaviours. This discrepancy may be due to differences in
the populations studied: in our study we included individuals at
high risk eligible for predictive genetic testing whereas Alagna et
al’s (1987) study included relatives of cancer patients who may
not have been at risk themselves. We did not ﬁnd a relationship
between perceived risk and risk management behaviour as reported
by Kash et al (1995). As previously stated this may be due in part
to the low variation in perceived risk scores in our cohort. These
differences may also be due to the age of our cohort. Younger
women (550 years) are more likely to report cancer related worry
but are not necessarily eligible for mammography due to their age.
In this cohort younger women are less likely to have had mammo-
graphy than older women which reﬂects current screening
guidelines. Women of all ages can perform BrSE therefore the rela-
tionship between health behaviour and cancer worry can be
demonstrated.
With regards prophylactic surgery, more women have had and
will consider prophylactic oophorectomy than mastectomy and
younger women are more likely to consider prophylactic mastect-
omy than older women. In the older age group (550 years) a
substantial proportion of women have already had prophylactic
oophorectomy. It is likely that prior to the availability of genetic
testing prophylactic oophorectomy was chosen as a form of risk
management in this group of high risk women in the absence of
carrier status information. Actual uptake of risk management
options following genetic testing will be established at follow-up.
In this cohort cancer worry is not associated with consideration
of prophylactic surgery. This is in contrast to other studies indicat-
ing that women with high levels of general anxiety (Lodder et al,
1999) and cancer speciﬁc worry (Stefanek, 1995) are more likely
to consider prophylactic mastectomy. Women with HBOC who
choose prophylactic mastectomy have been shown to be less
anxious than those who do not (Hatcher et al, 2001). The number
of women who indicated that they would consider this surgery was
lower than that reported by Lodder et al (1999). While prophylac-
tic surgery is still somewhat controversial, evidence suggests that
risk is signiﬁcantly reduced for women at high risk (Hartmann et
al, 1999) and therefore offers hope that their risk of cancer will
be reduced despite the presence of the BRCA1/2 mutation.
Given that one aim of predictive testing for BRCA1/2 is to
reduce mortality by regular surveillance or surgery it is important
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appropriate risk management behaviour. The most common
barrier to screening reported by the women is taking time off from
their usual obligations therefore practical steps can be taken to help
women overcome such hurdles such as mobile mammography
units that can be used by women under 50 years where appropri-
ate.
Motivation for testing
As with Lodder et al (1999) ﬁndings, the most commonly reported
motivation for testing was for the sake of children. Females were
more likely than men to want the test in order to prepare for
the future and alleviate uncertainty. This indicates that women
are thinking of their own risk as well as that of their children,
unlike the men who are not at greatly increased risk. Traditional
gene carrier testing and genetic counselling for late onset disease
differ in that traditional genetic counselling typically focuses on
risk to offspring while genetic counselling for susceptibility to
breast/ovarian cancer involves personal risk information in addi-
tion to potential risk to offspring (Lerman et al, 1994). Younger
women were more likely to give ‘to prepare for the future’ than
older women. Childless men and women were more likely to give
‘decisions about having children’ than parents. At present prenatal
carrier testing is not available for BRCA1/2 however it may become
part of clinical practice in the future.
This study contributes to the psycho-oncology literature by
investigating a large cohort including men and consisting mainly
of individuals that have not come from well-researched families
but from current clinical practice. We believe that this cohort
represents a population of individuals now coming forward for
BRCA1/2 testing who are new to this process. Most participants
were recruited from three UK centres with established genetics
services. Other centres were setting up their services during the
recruitment phase of the study. Most participants were pre-meno-
pausal women. This reﬂects ﬁndings from other studies (Lerman et
al, 1997; Reichelt et al, 1999). Little is known about men coming
forward for BRCA1/2 testing. Our sample includes a substantial
group of men, most of whom are under 50 years of age and have
children. Most men report initiating their referral to the genetics
clinic, although relatives suggested a referral for a signiﬁcant
minority.
In summary, these data illustrate that while general mental
health is not adversely affected by the prospect of predictive genetic
testing, cancer related worry is particularly prevalent amongst pre-
menopausal women many of whom self-refer to genetics services.
In the future genetic testing is likely to become more rapid and
more widely available. Given that many of the individuals in this
cohort experience frequent and troublesome cancer worry and
perceive themselves to be at high risk it is important that they
continue to receive genetic counselling prior to testing in order
to address concerns, receive information to make informed choices
and continue to be supported both medically and psychologically.
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